Company Description

Areteia, created through the merger of Knopp Biosciences and Population Health Partners, is a clinical-stage biotechnology company engaged in the development and delivery of a potential first-in-class oral therapy for inflammatory airway diseases, with an initial focus on severe eosinophilic asthma and eosinophilic chronic obstructive pulmonary disease.